Claris receives ANDA approval for Bupivacaine Injection

27 Jul 2016 Evaluate

Claris Lifesciences along with its subsidiaries (Claris) has received the Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose Injection USP, 7.5 mg/mL, Single-dose Ampules with 2ml fill volumes, in the United States of America (US).

With this approval, Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $300 million. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.

Bupivacaine Hydroxhloride in Dextorse Injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.


Peers
Company Name CMP
Adani Enterprises 3060.00
Redington 210.50
Amrapali Industries 15.15
Rashi Peripheral 327.80
Compuage Infocom 4.36
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.